Bosnar Luke M, Shindler Anya E, Wood Jennifer, Patch Craig, Franks Ashley E
Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Melbourne, Victoria 3086, Australia.
School of Allied Health, Human Services, and Sport, La Trobe University, Melbourne, Victoria 3086, Australia.
Access Microbiol. 2023 May 26;5(5):acmi000419. doi: 10.1099/acmi.0.000419. eCollection 2023.
The use of bacterial spores in probiotics over viable loads of bacteria has many advantages, including the durability of spores, which allows spore-based probiotics to effectively traverse the various biochemical barriers present in the gastrointestinal tract. However, the majority of spore-based probiotics developed currently aim to treat adults, and there is a litany of differences between the adult and infant intestinal systems, including the immaturity and low microbial species diversity observed within the intestines of infants. These differences are only further exacerbated in premature infants with necrotizing enterocolitis (NEC) and indicates that what may be appropriate for an adult or even a healthy full-term infant may not be suited for an unhealthy premature infant. Complications from using spore-based probiotics for premature infants with NEC may involve the spores remaining dormant and adhering to the intestinal epithelia, the out-competing of commensal bacteria by spores, and most importantly the innate antibiotic resistance of spores. Also, the ability of to produce spores under duress may result in less perishing within the intestines and releasing membrane branched-chain fatty acids. The isolate BG01-4 is a proprietary strain developed by Vernx Biotechnology through accumulating mutations within the BG01-4 genome in a serial batch culture. Strain BG01-4 was provided as a non-spore-forming , but a positive sporulation status for BG01-4 was confirmed through testing and suggested that selection for the sporulation defective genes could occur within an environment that would select against sporulation. The durability of key sporulation genes was ratified in this study, as the ability of BG01-4 to produce spores was not eliminated by the attempts to select against sporulation genes in BG01-4 by the epigenetic factors of high glucose and low pH. However, a variation in the genes in isolate BG01-4-8 involved in the regulation of sporulation is believed to have occurred during the mutation selection from the parent strain BG01-4. An alteration in selected sporulation regulation genes is expected to have occurred from BG01-4 to BG01-4-8, with BG01-4-8 producing spores within 24 h, ~48 h quicker than BG01-4.
在益生菌中使用细菌孢子而非活菌具有诸多优势,包括孢子的耐久性,这使得基于孢子的益生菌能够有效穿越胃肠道中存在的各种生化屏障。然而,目前开发的大多数基于孢子的益生菌旨在治疗成年人,而成年人和婴儿的肠道系统存在诸多差异,包括婴儿肠道内观察到的不成熟和微生物种类多样性低。这些差异在患有坏死性小肠结肠炎(NEC)的早产儿中只会进一步加剧,这表明适合成年人甚至健康足月儿的东西可能并不适合不健康的早产儿。对患有NEC的早产儿使用基于孢子的益生菌的并发症可能包括孢子保持休眠并附着在肠道上皮上、孢子与共生细菌竞争,以及最重要的是孢子固有的抗生素抗性。此外,在胁迫下产生孢子的能力可能导致在肠道内死亡的较少,并释放膜支链脂肪酸。分离株BG01 - 4是Vernx生物技术公司通过在连续分批培养中在BG01 - 4基因组内积累突变而开发的专有菌株。菌株BG01 - 4最初作为非产孢菌株提供,但通过测试确认了BG01 - 4的阳性产孢状态,并表明在不利于产孢的环境中可能会选择产孢缺陷基因。本研究证实了关键产孢基因的耐久性,因为高葡萄糖和低pH的表观遗传因素试图选择BG01 - 4中的产孢基因,但并未消除BG01 - 4产生孢子的能力。然而,据信在从亲本菌株BG01 - 4进行突变选择期间,分离株BG01 - 4 - 8中参与孢子形成调控的基因发生了变异。预计从BG01 - 4到BG01 - 4 - 8,选定的孢子形成调控基因会发生改变,BG01 - 4 - 8在24小时内产生孢子,比BG01 - 4快约48小时。